30 December 2019 - - US-based biotechnology company AgeX Therapeutics, Inc. (NYSE American: AGE) has drawn down a USD 1.3m tranche of financing pursuant to its unsecured loan facility from Juvenescence Ltd., the company said.

As the company announced on August 14, 2019, AgeX has obtained a USD 2m credit facility from Juvenescence to finance AgeX's operations and advance its product development programmes.

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a range of diseases with a high unmet medical need.

AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX's revolutionary longevity platform induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.

AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeX's delivery technology to stably engraft PureStem cell therapies in the body.

AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.